Konfer Launches DORA Compliance Controls Catalog to Help EU Meet January 2025 Compliance Deadline, Partners With Leading Law Firm Osborne Clarke to Offer DORA Compliance Check to EU Organizations
10.9.2024 10:00:00 CEST | Business Wire | Press release
Konfer, the Silicon Valley-based Agentic AI product company, today announced the launch of the Konfer DORA Compliance Controls Catalog to help EU financial institutions meet the January 2025 conformance deadline.
The Konfer DORA Control Questions Catalog is designed to guide financial institutions through the complexities of the Digital Operational Resilience Act (DORA). Konfer’s AI agent has interpreted DORA’s extensive regulation, converting the obligations into practical control questions. These questions not only assess compliance but also integrate team responses to provide a detailed view of an organization's operational resilience, identifying potential vulnerabilities, and enhancing risk management processes.
“The Konfer DORA Controls Catalog was designed to help EU financial institutions not just get a translation of the DORA compliance, but to actively implement the controls across their teams and operationalize compliance,” said Debu Chatterjee, CEO of Konfer. “It takes out guess-work or interpretation gaps, and empowers ICT and compliance leaders with a rubric for conformance, with the shortest time-to-value, given the approaching January 2025 deadline.”
IT leaders and Compliance executives in the EU financial institutions are required to specify the elements which a financial entity needs to determine and assess when subcontracting ICT services supporting critical or important functions. This puts the burden of collecting responses from third party vendors, analyzing the responses, and identify vulnerabilities on the financial institution. “With Konfer Clear for DORA, executive leadership can now gain complete visibility into their third-party vendors’ compliance, and proactively require them to upgrade and maintain their resiliency,” continued Chatterjee. “Our focus is to help operationalize compliance—whether internally or with external vendors—so that the compliance teams are able to focus on risk analysis, vulnerability assessments, and proactive remediation rather than on repetitive tasks.”
Konfer has partnered with leading law firm Osborne Clarke Netherlands to develop DORA Compliance Check for the firm’s clients. The law firm will leverage Konfer Clear to provide clients with advice on their DORA Compliance requirements, gaps, and confidence score.
“We are pleased to partner with Konfer, and look forward to enabling our clients to accelerate their DORA compliance time-to-completion, using Konfer Clear,” said Johannes de Jong, Financial Regulatory partner at Osborne Clarke Netherlands. “This online tool will help our clients to rapidly upload their compliance documents and receive a Clear scorecard, thereby providing valuable insights for their ICT contract management.”
Konfer DORA Compliance Controls is easily embedded into workflows, and is able to connect with the financial institutions internal and external ICT systems. The AI-powered suite is able to rapidly analyze gaps, compare with any new updates to the compliance mandates, and alert IT and compliance leaders.
The DORA Compliance Controls can be downloaded from https://konfer.ai/acts/finance/
About Konfer: Based in Milpitas, CA, Konfer is a venture-backed Agentic AI product that delivers governance workflows to manage the explosion of regulations across the world in a standard scalable way.
About Osborne Clarke: Osborne Clarke is an international, full-service law firm with over 330 partners and more than 1,630 legal experts working across 26 global locations. We combine the personalised service of a local office with the resources and reach of a large international firm, providing effective solutions for complex issues. Osborne Clarke has an impressive client base in the sectors of Energy & Utilities, Financial Services, Life Sciences & Healthcare, Mobility & Infrastructure, Retail & Consumer, Tech, Media & Comms, The Built Environment, and Workforce Solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910605198/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom